Discovering Impactful Medicines: Many Paths, Same Goal

Join the UH Drug Discovery Institute for this hybrid event. A Zoom link will be emailed to registered attendees.

About the Event

In this presentation, Sharath Hegde will provide an overview of the drug-discovery process, its challenges and opportunities, and share his personal perspectives on the key drivers of success. He will also use historical precedents and draw on his own experience to illustrate the many paths one can take to discover impactful medicines.

About the Speaker

Sharath S. Hegde, Ph.D., is currently Chief Scientific Officer at Congruence Therapeutics and a passionate drug hunter who has participated in the discovery of several NCEs including the marketed medicines Vibativ® (telavancin), Yupelri® (revefenancin), Aloxi® (palanosetron) and others in late-stage development including ampreloxetine and REC-3964.

After obtaining his BPharm and MPharm (Pharmacology) from the University of Mumbai, Sharath moved to US for his doctoral studies and obtained his PhD in Pharmacology from the University of Houston (Class of 1990) under the mentorship of Dr. Mustafa Lokhandwala.

Sharath has over 30 years of leadership experience (Roche, Theravance Biopharma, Recursion, Herophilus) in strategic and tactical aspects of drug-discovery and early clinical development. He has been trained in classical ‘integrated pharmacology’. He possesses extensive experience in seeding new project ideas and driving the discovery of first-in-class/best-in-class drugs in multiple therapeutic areas including rare, infectious, cardiovascular, respiratory, genitourinary, gastrointestinal, neuroscience, fibrosis, oncology, autoimmune and inflammatory diseases. He is the co-author of over 50 scientific publications.